Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification among Patients with Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-Income Countries

Kathryn Dupnik¹, Vanessa R. Rivera², Nancy Dorvil², Hanane Akbarnejad³, Yipeng Gao³, Jingyi Liu³, Alexandra Apollon², Emelyne Dumond², Cynthia Riviere², Patrice Severe², Kerlyne Lavoile², Maria Alejandra Duran Mendicuti⁴, Samuel Pierre², Vanessa Rouzier^{1,5}, Kathleen F. Walsh¹, Anthony L. Byrne⁵, Patrice Joseph², Pierre-Yves Cremieux³, Jean William Pape^{1,5}, Serena P. Koenig⁴

¹Weill Cornell Medicine, New York, New York, USA;

²Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;

³The Analysis Group, Boston, Massachusetts, USA;

⁴Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA;

⁵St. Vincent's Hospital and Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia

Corresponding Author Serena P. Koenig Brigham and Women's Hospital 75 Francis Street Boston, MA 02115, USA Phone: 617-413-4090 Email: skoenig@bwh.harvard.edu

Word Count: 250 abstract, 2928 text; 4 tables, 2 figures, 1 supplemental table Key Words: HIV, tuberculosis, C-reactive protein

Article Summary:

We assessed the association between C-reactive protein (CRP) and *Mycobacterium tuberculosis* (TB) diagnosis in symptomatic patients at HIV diagnosis. We found that CRP concentrations can improve tuberculosis risk stratification, facilitating decision making about whether (specific) tuberculosis testing is indicated before antiretroviral therapy initiation.

ABSTRACT

Background: The World Health Organization recommends initiating same-day ART while tuberculosis testing is underway for patients with non-meningitic symptoms at HIV diagnosis, though safety data are limited. C-reactive protein (CRP) testing may improve tuberculosis risk stratification in this population. **Methods:** In this baseline analysis of 498 adults (>18 years) with tuberculosis symptoms at HIV diagnosis who were enrolled in a trial of rapid ART initiation in Haiti, we describe test characteristics of varying CRP thresholds in the diagnosis of TB. We also assessed predictors of high CRP (\geq 3 mg/dL) using generalized linear models.

Results: Eighty-seven (17.5%) patients were diagnosed with baseline TB. The median CRP was 33.0 mg/L (IQR: 5.1, 85.5) in those with TB, and 2.6 mg/L (IQR: 0.8, 11.7) in those without TB. As the CRP threshold increased from \geq 1 mg/L to \geq 10 mg/L, the positive predictive value for TB increased from 22.4% to 35.4%, and negative predictive value decreased from 96.9% to 92.3%. With CRP thresholds varying from <1 to <10 mg/L, a range from 25.5% to 64.9% of the cohort would have been eligible for same-day ART, and 0.8% to 5.0% would have untreated TB at ART initiation.

Conclusions: CRP concentrations can be used to improve TB risk stratification, facilitating same-day decisions about ART initiation. Depending on the CRP threshold, one-quarter to two-thirds of patients could be eligible for same-day ART, with a reduction of 3-fold to 20-fold in the proportion with untreated TB, compared with a strategy of same-day ART while awaiting TB test results.

INTRODUCTION

Global guidelines recommend antiretroviral therapy (ART) initiation on the same day of HIV diagnosis for patients who are ready to start treatment.¹⁻⁴ These guidelines have been implemented in response to several clinical trials and cohort studies, which have demonstrated improved outcomes and faster time to viral suppression with this approach.⁵⁻⁹ However, a substantial proportion of patients in high burden settings present with symptoms of tuberculosis (TB) at HIV diagnosis.^{10,11} The World Health Organization (WHO) recommends a four-symptom screen (W4SS) for cough, fever, night sweats and/or weight loss prior to ART initiation, followed by rapid molecular TB testing in symptomatic patients.¹ However, it is logistically challenging to complete a TB evaluation in one day, as the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) has at least a two-hour turnaround time, and tests are often conducted in centralized laboratories.¹² Furthermore, the specificity of the W4SS is low (42% in a recent meta-analysis); consequently, this approach results in additional visits for test results and delays in ART initiation for patients who do not have active TB.

To avoid delays in ART initiation, the current WHO guidelines include a clinical consideration to initiate same-day ART while investigating for TB in patients with presumptive TB (without symptoms of central nervous system involvement).¹ However, data on the safety of initiating ART in the presence of undiagnosed TB are limited.¹³ A clinical trial is currently underway in patients who report at least one symptom on the W4SS at HIV diagnosis in Lesotho and Malawi to compare outcomes with a strategy of waiting for TB test results vs. immediately initiating ART.¹⁴

An alternative approach would be to conduct a rapid point-of-care test for symptomatic patients at HIV diagnosis to further improve TB risk profiling, so that TB testing can be prioritized for high-risk patients, and immediate ART can be initiated in low-risk patients. Rapid point-of-care C-reactive protein (CRP) tests could be particularly well suited for this indication, because they are inexpensive (\$2 USD/test), generate results in 3 minutes, and can be performed with a fingerstick specimen.¹⁵ Multiple studies have reported that CRP has superior diagnostic characteristics for the detection of TB at the time of HIV diagnosis, compared with the W4SS alone.¹⁶⁻¹⁹ The WHO conditionally recommends the use of CRP with a cut-off of 5mg/L to screen for active TB in PLWH, with the caveat that more data are needed.¹ However, CRP testing is not widely available in HIV clinics, and is not included in decision-making algorithms about the timing of ART initiation. Therefore, we conducted a study to evaluate the association between CRP levels and active TB among symptomatic patients at HIV diagnosis at the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) in Port-au-Prince, Haiti.

METHODS

This study included data from a previously published trial, in which persons with non-meningitic TB symptoms at HIV diagnosis were randomized to receive same-day treatment (same-day TB testing with same-day TB treatment if TB diagnosed; same-day ART if TB not diagnosed) vs. standard care (initiating TB treatment within 7 days and delaying ART to Day 7 if TB not diagnosed).¹¹ Patients were eligible for study inclusion if they were infected with HIV-1, \geq 18 years of age, non-pregnant, ART-naïve, and reported cough, fever, and/or night sweats of any duration, and/or weight loss which was confirmed by the study physician.

At HIV diagnosis, complete blood count (Abbott, Abbott Park, Illinois), CD4 count (FACSCount, Becton Dickinson, Franklin Lakes, NJ), digital chest radiograph, Xpert Ultra (Cepheid, Sunnyvale, CA) and liquid mycobacterial culture (Mycobacteria Growth Indicator Tube [MGIT], BACTEC, Becton Dickinson) were conducted for all participants; Xpert Ultra and mycobacterial culture were performed on both spot and early morning specimens. Sera were stored for CRP testing; specimens were processed within 4 hours of collection, biobanked at -80°C, and shipped to Weill Cornell Medical College for testing (CRP Quantikine ELISA Kit, R&D Systems, Minneapolis, MN). The manufacturer's protocol was followed with the following specifications. Serum samples were thawed and serially diluted 1:100 followed by 1:5 to make a final dilution of 1:500 for each sample. The 1:100 dilution was saved for subsequent tests if samples needed to be repeated. Absorbance was measured at 450 nm with 540 nm correction. A standard curve (minimum: 3.9 mg/L, maximum: 25 mg/L) and three positive controls with varying concentration were included in each assay performed. Samples that had a CRP reading above 25 mg/L were re-tested at a 1:2,500 or 1:10,000 dilution for each sample.

CRP testing was conducted retrospectively, so results were not available to guide decision making. All participants in both groups received initial TB test results prior to ART or TB treatment initiation; participants in the same-day treatment group received same-day TB test results, which is not standard of care at GHESKIO.

This study was approved by the institutional review boards at GHESKIO, Mass General Brigham, and Weill Cornell Medical College. Written informed consent was obtained from all participants.

Statistical Analysis

Demographic, clinical and laboratory information were extracted from the GHESKIO electronic medical record. Baseline characteristics were summarized by tuberculosis status using medians and interquartile ranges (IQR) for continuous variables and counts and percentages for categorical variables. Age, body mass index (BMI), hemoglobin, and CD4 count were continuous variables. Sex, income, education, TB symptoms, Xpert Ultra and culture results, and radiographic abnormalities were binary or categorical variables. Patients were classified as having bacteriologically-confirmed TB if they had a positive Xpert Ultra test and/or mycobacterial culture. Patients were classified as having empirically diagnosed TB if they had symptoms and chest radiograph which were consistent with TB, without bacteriologic confirmation.

We calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV), and positive and negative likelihood ratios of varying CRP thresholds (≥ 1.0 , ≥ 2.0 , ≥ 5.0 , ≥ 10.0 mg/L) in the diagnosis of TB in the total cohort of symptomatic patients, and stratified by symptoms (cough, fever, and/or night sweats vs. weight loss only). We also calculated these test characteristics in the diagnosis of bacteriologically-confirmed TB. In addition, we assessed predictors of high CRP (≥ 3 mg/dL) in the total cohort, and predictors of high (≥ 3 mg/L) vs. low (<3 mg/L) CRP among patients diagnosed with TB, using generalized linear models.

RESULTS

Five hundred participants were enrolled in the trial from November 6, 2017 to January 16, 2020; of these 498 (99.6%) had a CRP test result at HIV diagnosis, and were included in the analysis. Median age was 37 years (IQR: 30, 45), 234 (46.8%) were female, and median body mass index (BMI) was 20.7 (IQR 18.7, 22.9). Median hemoglobin was 11.2 g/dL (IQR: 9.9, 12.3) in females and 12.7 g/dL (10.6, 14.3) in males; median CD4 count was 276 cells/mm³ (IQR: 128, 426), and median CRP was 3.9 mg/L (IQR: 1.0, 18.7) (see **Table 1**). A total of 260 participants (52.2%) reported cough, fever, and/or night sweats (+/-weight loss) and 238 (47.8%) reported isolated weight loss.

At enrollment, 87 (17.5%) patients were diagnosed with TB; 67 (13.5%) had bacteriologically-confirmed TB and 20 (4.0%) had empirically-diagnosed TB. Patients diagnosed with baseline TB were more likely to report cough, fever, and/or night sweats (vs. isolated weight loss), and had lower BMI, hemoglobin, and CD4 cell counts, compared to those not diagnosed with TB (see **Table 1**). Median CRP was 33.0

mg/L (IQR: 5.1, 85.5) in those diagnosed with TB, and 2.6 mg/L (IQR: 0.8, 11.7) in those without TB. Any radiographic abnormality consistent with pulmonary TB was detected in 45 (51.7%) of participants diagnosed with TB, and 27 (6.6%) of those without TB.

A total of 267 (53.6%) patients had baseline CRP levels of \geq 3.0 mg/L. In multivariable analysis, elevated CRP levels (\geq 3.0 mg/L) were significantly associated with cough/fever/night sweats vs. isolated weight loss (adjusted odds ratio [aOR] 2.01; 95% confidence interval [CI]: 1.33, 3.07), lower CD4 count (aOR: 0.90 per 50 cells/mm³; 95% CI: 0.85, 0.94), lower hemoglobin (aOR: 0.98 per g/dL; 95% CI: 0.97, 1.00) and TB versus no TB diagnosis (aOR:3.50, 95% CI: 1.68, 7.89) (see **Table 2**).

Among patients with TB, we conducted univariable analyses to compare those with lower CRP (<3 mg/L) versus higher CRP (\geq 3 mg/L). There was no significant difference in any of the variables assessed, including sex, age, symptoms, BMI, CD4 count, hemoglobin, sputum results, or radiographic findings (see **Table 3**).

We assessed the impact of a range of CRP thresholds on the PPV and NPV of baseline TB in this cohort of symptomatic patients (see **Table 4**). As the CRP threshold increased from $\geq 1 \text{ mg/L}$, to $\geq 3 \text{ mg/L}$, $\geq 5 \text{ mg/L}$ and $\geq 10 \text{ mg/L}$, the PPV for TB in the total cohort increased from 22.4% to 28.1%, 29.2%, and 35.4%, respectively, and the NPV decreased from 96.9% to 94.8%, 92.3%, and 92.3%. **Supplementary Table 1** includes these results in patients with bacteriologically-confirmed TB.

Among the 260 participants with cough, fever, and/or night sweats (+/- weight loss), the prevalence of baseline TB was 30%. The PPV for TB increased from 34.7% to 40.0%, 41.2%, and 45.7%, as the CRP threshold increased from ≥ 1 mg/L, to ≥ 3 mg/L, ≥ 5 mg/L and ≥ 10 mg/L, respectively, and the NPV decreased from 91.5% to 88.9%, 86.0%, and 85.5%.

Among the 238 participants with isolated weight loss (i.e., excluding those with cough, fever, and/or night sweats), the prevalence of TB was 3.8%. The PPV was only 6.5% at CRP threshold of \geq 10 mg/L. The NPV for TB decreased from 100% at a CRP threshold of \geq 1 mg/L, to 98.6%, 96.4%, and 96.9% at thresholds of \geq 3 mg/L, \geq 5 mg/L and \geq 10 mg/L, respectively.

CRP testing was conducted retrospectively, so results were not available at enrollment in the parent trial; in accordance with the study protocol, all 498 patients had TB testing prior to ART initiation. If we had implemented the WHO-recommended strategy of ART initiation prior to completion of TB testing, then 87 (17.5%) patients would have started ART with untreated TB. If we had included CRP concentrations in our same-day ART eligibility algorithm, then with CRP thresholds of <1, <2, <3, <5, and <10 mg/L, a total of 127 (25.5%), 190 (38.2%), 231 (46.4%), 272 (54.6%), and 323 (64.9%) patients would have been eligible for same-day ART (see **Figure 1**). A total of 4 (0.8%), 11 (2.2%), 12 (2.4%), 21 (4.2%), and 25 (5.0%) patients, respectively, would have had untreated active TB at ART initiation (active TB in spite of having CRP levels below the cut-off).

Among the 260 patients who reported cough, fever, and/or night sweats (+/- weight loss), if same-day ART had been initiated while TB testing was underway, then 78 (30.0%) would have started ART with untreated TB. If CRP thresholds of <1, <2, <3, <5, and <10 mg/L had been used as eligibility thresholds, then 47 (17.5%), 73 (28.1%), 90 (34.6%), 107 (41.2%), and 131 (50.4%) patients, respectively would have been eligible for same-day ART (see **Figure 2A**). A total of 4 (1.5%), 10 (3.8%), 10 (3.8%), 15 (5.8%), and 19 (7.3%) patients, respectively, would have had untreated TB at ART initiation.

Among the 238 patients who reported isolated weight loss, 9 (3.8%) were diagnosed with baseline TB. If CRP thresholds of <1, <2, <3, <5, and <10 mg/L had been used as same-day ART eligibility thresholds, then 80 (33.6%), 117 (49.2%), 141 (59.2%), 165 (69.3%), and 192 (80.7%) patients, respectively would have been eligible for same-day ART (see **Figure 2B**). A total of 0 (0.0%), 1 (0.4%), 2 (0.8%), 6 (2.5%), and 6 (2.5%) patients, respectively, would have had untreated TB at ART initiation.

DISCUSSION

We found that CRP concentrations can be used to stratify symptomatic patients into high or low risk of TB at HIV diagnosis, facilitating decision making about same-day ART initiation. The WHO currently recommends the W4SS screen at HIV diagnosis, with two guideline-approved algorithms for symptomatic patients – either same-day ART while awaiting TB test results, or deferral of ART until completion of TB testing.¹ However, these approaches either result in ART initiation in patients with undiagnosed TB, or unnecessary delays in ART for those without TB. In our cohort, the prevalence of baseline TB was 17.5%, and the PPV of CRP was 22.4%, 28.1%, 29.2%, and 35.4% at thresholds ≥ 1 mg/L, ≥ 3 mg/L, ≥ 5 mg/L and ≥ 10 mg/L, respectively. With the use of CRP-based eligibility criteria, one-quarter to two-thirds of symptomatic patients could be eligible for same-day ART, depending on the CRP threshold used, with a 3-fold to 20-fold reduction in the proportion of patients with undiagnosed TB at ART initiation, compared with the WHO strategy of same-day ART prior to completion of TB testing.

We also found that baseline TB prevalence varied by W4SS symptom category. About half of the total cohort reported cough, fever, and/or nights sweats (+/- weight loss), and nearly half reported isolated weight loss. The prevalence of TB in those with cough, fever, and/or night sweats was almost 10-fold higher than that of the patients who reported isolated weight loss (30.0% vs. 3.8%). Among patients with cough, fever, and/or night sweats, the PPV of CRP was 40.0%, 41.2%, and 45.7% at thresholds \geq 3 mg/L, \geq 5 mg/L and \geq 10 mg/L, respectively. If CRP values under these thresholds were used to define same-day ART eligibility, then one-third to one-half of this subgroup would be eligible for same-day ART, with a 4-fold to 8-fold reduction in the proportion of patients with undiagnosed TB at ART initiation, compared with the strategy of same-day ART testing prior to completion of TB testing.

In contrast, among patients with isolated weight loss, the PPV is low at all CRP thresholds, but the NPV is high; with CRP thresholds of <1, <2, or <3, up to about 60% of patients would be eligible for same-day ART initiation, with <1% of patients having baseline TB and CRP concentrations below these cut-offs. A study conducted among ART-naïve patients in South Africa also reported that the NPV of CRP <1 mg/L was 100%.²⁰ These data suggest that clinicians can confidently commence ART in patients with a new diagnosis of HIV with isolated weight loss as a symptom and low CRP. In fact, from our study, less than 1% of patients with this clinical picture and a CRP <3 mg/L were found to have TB.

Multiple studies of ART-naïve patients in African cohorts that included mycobacterial culture have reported a TB prevalence similar to ours.²¹⁻²⁵ Most studies that reported 4WSS results combined all four symptoms.²⁶ Among those that reported individual symptoms, other studies have also reported a lower TB prevalence among patients reporting isolated weight loss, compared with cough, fever, and/or night sweats. In a clinical trial cohort of newly diagnosed patients from South Africa and Kenya, the PPV value of cough and fever was over 30% versus about 5% for isolated weight loss.²⁷ A cohort study from Ethiopia found that cough was the most predictive of active TB.²⁵

We are not aware of any HIV program which uses CRP in decision making about the timing of ART initiation. Multiple studies have demonstrated CRP has similar sensitivity but greater specificity than the W4SS, but these studies were conducted to assess alternative strategies for more efficient use of TB diagnostic testing.¹⁶⁻²⁰ Current WHO guidelines provide a conditional recommendation (low-certainty evidence for test accuracy) for CRP with a cut-off of >5 mg/L to screen for TB disease in PLWH.¹ However, CRP is not included in the algorithms for same-day ART initiation.

The sensitivity and specificity of the W4SS are about 82% and 42%, respectively.^{19,26} In a systematic review and individual participant data meta-analysis commissioned by the WHO, the investigators found that among outpatients not on ART, the sensitivities of CRP ($\geq 10 \text{ mg/L}$) and a sequential strategy of W4SS followed by CRP ($\geq 5 \text{ mg/L}$) were similar to W4SS alone, but the specificities were higher.¹⁹ A study from Uganda found that point-of-care CRP had 89% sensitivity and 72% specificity for culture-confirmed TB.¹⁷ A study from South Africa reported that the sensitivity and specificity of CRP >5 for culture-positive TB were 91% and 59%, respectively.¹⁶ Among our cohort of patients with positive W4SS symptom screens, the sensitivity of CRP was higher at threshold of $\geq 3 \text{ mg/L}$ versus $\geq 5 \text{ mg/L}$ (86% vs. 76%), with a slight decline in specificity (53% vs. 61%).¹⁹

These findings highlight the potential utility of CRP testing to inform decision making about same-day ART initiation in patients who present with TB symptoms at HIV diagnosis. CRP is available as a simple, rapid, low-cost (<\$US 2), point-of-care test, which is available from a variety of manufacturers.¹⁵ Further study is necessary to define optimal CRP thresholds, which may potentially vary by number and type of symptoms. Moreover, CRP would not replace diagnostic testing for TB or other opportunistic infections and non-communicable diseases.

Our study was conducted among non-pregnant participants in a large, urban clinic, which may limit the generalizability of our findings. It is also important to note that we used a more aggressive diagnostic approach for TB than is provided in many high-burden settings. However, in settings without access to mycobacterial culture and chest radiographs, the detection of a high CRP level (>5mg/L or >10 mg/L for example) can alert providers to a potential case of TB or other opportunistic infection, even if sputum smear or Xpert MTB/RIF testing is negative. Among patients with isolated weight loss without respiratory symptoms or fever, the clinician and program can have even greater confidence in commencing ART (and not missing a TB diagnosis) in the presence of a low CRP.

In conclusion, our results demonstrate that CRP testing can be useful in stratifying patients with nonmeningitic symptoms into high or low risk of TB at HIV diagnosis, facilitating decision making about same-day ART initiation.

ACKNOWLEDGEMENTS

We thank the patients who participated in this study and the GHESKIO staff who cared for them. We also thank the members of the Data Safety Monitoring Board, the Community Advisory Board, and the ethics committees for their expertise and advice. This study was funded by a grant from the National Institute of Allergy and Infectious Diseases (R01AI131998; primary investigator: SK). KD was supported by NIAID (K23AI131913) and a Doris Duke Charitable Foundation Clinical Scientist Development Award.

All authors were involved in drafting the article, and all approved the final version to be published. Study conception and design: KD, VRR, ND, CR, PS, SP, KFW, PJ, JWP, SPK. Acquisition of data: ND, AA, ED, CR, PS, KL, SP, VR. Analysis and interpretation of data: KD, VRR, ND, HA, YG, JL, MDM, KFW, ALB, PYC, JWP, SPK. There are no conflicts of interest.

REFERENCES

1. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach, July 2021. Accessed November 5, 2023 at: <u>https://www.who.int/publications/i/item/9789240031593</u>.

2. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. *JAMA*. Jan 3 2023;329(1):63-84. doi:10.1001/jama.2022.22246

3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Accessed on November 5, 2023 at: <u>https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new</u>.

4. European AIDS Clinical Society (EACS) Guidelines Version 12.0, October 2023. Access on November 5, 2023 at: <u>https://www.eacsociety.org/media/guidelines-12.0.pdf</u>.

5. Koenig SP, Dorvil N, Devieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. *PLoS Med.* Jul 2017;14(7):e1002357. doi:10.1371/journal.pmed.1002357

 Labhardt ND, Ringera I, Lejone TI, et al. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial. *JAMA*. Mar 20 2018;319(11):1103-1112. doi:10.1001/jama.2018.1818

7. Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. *Lancet HIV*. Nov 2016;3(11):e539-e548. doi:10.1016/S2352-3018(16)30090-X

8. Rosen S, Maskew M, Fox MP, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. *PLoS Med.* May 2016;13(5):e1002015. doi:10.1371/journal.pmed.1002015

9. Coffey S, Bacchetti P, Sachdev D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. *AIDS*. Apr 1 2019;33(5):825-832. doi:10.1097/QAD.00000000002124

10. Rosen S, Maskew M, Larson BA, et al. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya. *PLoS Med.* Sep 2019;16(9):e1002912. doi:10.1371/journal.pmed.1002912

11. Dorvil N, Rivera VR, Riviere C, et al. Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti. *PLoS Med.* Jun 2023;20(6):e1004246. doi:10.1371/journal.pmed.1004246

12. Maskew M, Brennan AT, Fox MP, et al. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. *PLoS Med.* Aug 2020;17(8):e1003226. doi:10.1371/journal.pmed.1003226

13. Burke RM, Rickman HM, Singh V, et al. Same-day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review. *HIV Med*. Jan 2022;23(1):4-15. doi:10.1111/hiv.13169

14. Same-Day Versus Rapid ART Initiation in HIV-positive Individuals Presenting with Symptoms of Tuberculosis (SaDAPT). ClinicalTrials.gov ID: NCT0542616. Accessed November 5 at:

https://www.clinicaltrials.gov/study/NCT05452616?distance=50&cond=hiv&term=tuberculosis &intr=same%20day&rank=2.

15. Calarco S, Fernandez-Carballo BL, Keller T, et al. Analytical performance of 17 commercially available point-of-care tests for CRP to support patient management at lower levels of the health system. *PLoS One*. 2023;18(1):e0267516. doi:10.1371/journal.pone.0267516

16. Shapiro AE, Hong T, Govere S, et al. C-reactive protein as a screening test for HIVassociated pulmonary tuberculosis prior to antiretroviral therapy in South Africa. *AIDS*. Aug 24 2018;32(13):1811-1820. doi:10.1097/QAD.000000000001902

17. Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. *Lancet Infect Dis.* Dec 2017;17(12):1285-1292. doi:10.1016/S1473-3099(17)30488-7

Yoon C, Semitala FC, Asege L, et al. Yield and Efficiency of Novel Intensified
 Tuberculosis Case-Finding Algorithms for People Living with HIV. *Am J Respir Crit Care Med.* Mar 1 2019;199(5):643-650. doi:10.1164/rccm.201803-0490OC

19. Dhana A, Hamada Y, Kengne AP, et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. *Lancet Infect Dis.* Apr 2022;22(4):507-518. doi:10.1016/S1473-3099(21)00387-X

20. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum Creactive protein for screening for HIV-associated tuberculosis. *Int J Tuberc Lung Dis*. May 2013;17(5):636-43. doi:10.5588/ijtld.12.0811

21. Ahmad Khan F, Verkuijl S, Parrish A, et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. *AIDS*. Jun 19 2014;28(10):1463-72. doi:10.1097/QAD.0000000000278

22. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. *Clin Infect Dis*. Oct 1 2010;51(7):823-9. doi:10.1086/656282

23. Kerkhoff AD, Wood R, Lowe DM, Vogt M, Lawn SD. Blood neutrophil counts in HIVinfected patients with pulmonary tuberculosis: association with sputum mycobacterial load. *PLoS One*. 2013;8(7):e67956. doi:10.1371/journal.pone.0067956

24. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. *PLoS Med.* Jul 2011;8(7):e1001067. doi:10.1371/journal.pmed.1001067

25. Balcha TT, Skogmar S, Sturegard E, et al. A Clinical Scoring Algorithm for Determination of the Risk of Tuberculosis in HIV-Infected Adults: A Cohort Study Performed at Ethiopian Health Centers. *Open Forum Infect Dis*. Dec 2014;1(3):ofu095. doi:10.1093/ofid/ofu095

26. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. *Lancet HIV*. Sep 2018;5(9):e515-e523. doi:10.1016/S2352-3018(18)30137-1

27. Brennan A, Maskew M, Larson BA, et al. Prevalence of TB symptoms, diagnosis and treatment among people living with HIV (PLHIV) not on ART presenting at outpatient clinics in

South Africa and Kenya: baseline results from a clinical trial. *BMJ Open*. Sep 6 2020;10(9):e035794. doi:10.1136/bmjopen-2019-035794

Table 1. Baseline Characteristics by TB Status

Variable	Total Cohort	TB Cohort	Non-TB Cohort	p-value
	(n = 498)	(n= 87)	(n= 411)	
Female – no. (%)	234 (47.0)	33 (37.9)	201 (48.9)	0.081
Age (years) – median (IQR)	37 (30, 45)	36 (31, 43)	37 (30, 46)	0.531
Cough, fever, and/or night sweats – no. (%)	260 (52.2)	78 (89.7)	182 (44.3)	<0.001*
Body mass index – median (IQR)	20.7 (18.7, 22.9)	18.9 (17.7, 20.6)	21.1 (19.2, 23.3)	<0.001*
CD4 count category – no. (%)				0.028
<100 cells/mm ³	100 (20.3)	25 (29.4)	75 (18.4)	
100 to 349 $cells/mm^3$	224 (45.4)	39 (45.9)	185 (45.3)	
$350 \text{ to } 499 \text{ cells/mm}^3$	84 (17.0)	14 (16.5)	70 (17.2)	
\geq 500 cells/mm ³	85 (17.2)	7 (8.2)	78 (19.1)	
CD4 count – median (IQR)	276 (128, 426)	170 (86, 342)	288 (140, 444)	< 0.001*
Hemoglobin (g/dL) – median (IQR)	11.9 (10.1, 13.4)	9.4 (8.3, 11.0)	12.2 (10.7, 13.7)	< 0.001*
C-Reactive Protein (mg/L) – no. (%)				
≥1.0	371 (74.5)	83 (95.4)	288 (70.1)	<0.001*
≥2.0	308 (61.8)	76 (87.4)	232 (56.4)	< 0.001*

≥3.0	267 (53.6)	75 (86.2)	192 (46.7)	<0.001*
≥5.0	226 (45.4)	66 (75.9)	160 (38.9)	<0.001*
≥10.0	175 (35.1)	62 (71.3)	113 (27.5)	<0.001*
C-Reactive Protein (mg/L – median (IQR)	3.9 (1.0, 18.7)	33.0 (5.1, 85.5)	2.6 (0.8, 11.7)	<0.001*

Table 2. Predictors of Elevated C-Reactive Protein (<a>3.0 mg/dL)

Variable	Univariable Analysis		Multivariable Analysis		
	Odds Ratio (95% CI)	Odds Ratio (95% CI) p-value Adjusted Odds Ratio (95% CI)		p-value	
Female Sex	0.89 (0.63, 1.27)	0.534	0.73 (0.46, 1.15)	0.176	
Age (per decade)	1.15 (0.96, 1.38)	0.119	1.18 (0.96, 1.45)	0.114	
Cough, fever, and/or night sweats (vs. isolated weight loss)	2.75 (1.91, 3.96)	<0.001*	2.01 (1.33, 3.07)	0.001*	
Body mass index (per unit)	0.95 (0.90, 0.99)	0.024*	1.04 (0.98, 1.11)	0.186	
CD4 count (per 50 cells/mm ³)	0.89 (0.85, 0.92)	<0.001*	0.90 (0.85, 0.94)	<0.001*	
Hemoglobin (per g/dL)	0.97 (0.97, 0.98)	<0.001*	0.98 (0.97, 1.00)	0.005*	
Diagnosed with Tuberculosis	6.00 (3.11, 12.76)	<0.001*	3.50 (1.68, 7.89)	0.001*	

Variable	All Patients with TB (n=87)	CRP ≥3 (n=75)	CRP <3 (n=12)	p-value
Female – no. (%)	33 (37.9)	28 (37.3)	5 (41.7)	0.76
Age at enrollment (years) – median (IQR)	36 (31, 43)	36 (31, 42)	39 (33, 45)	0.662
Isolated weight loss (no cough, fever, or night sweats) – no (%)	9 (10.3)	7 (9.3)	2 (16.7)	0.605
Body mass index – median (IQR)	18.9 (17.7, 20.6)	18.8 (17.7, 20.7)	19.4 (17.7, 20.1)	0.849
CD4 count – median (IQR)	170 (86, 342) 177 (88, 317)		122.5 (70.8, 382.3)	0.686
CD4 count category – no. (%)				0.246
<100 cells/mm ³	25 (29.4)	20 (27.4)	5 (41.7)	
100 to 349 cells/mm ³	39 (45.9)	36 (49.3)	3 (25)	

 Table 3. Baseline Demographic and Clinical Characteristics among Patients with Tuberculosis, by C-Reactive Protein Level


\geq 350 cells/mm ³	21 (24.7)	17 (23.2)	4 (33.4)	
Hemoglobin (g/dL) – median (IQR)	9.4 (8.3, 11.0) 9.4 (8.2, 10.9)		9.1 (8.8., 11.7)	0.483
Xpert Ultra positive (2 samples)	37 (42.5)	33 (44.0)	4 (33.3)	0.704
Xpert Ultra positive (1 sample)	55 (63.2)	48 (64.0)	7 (58.3)	0.753
Xpert Ultra and/or culture positive	67 (77.0)	57 (76.0)	10 (83.3)	0.725
Any radiographic abnormality consistent with TB	45 (51.7)	40 (53.3)	5 (41.7)	0.66


CRP Threshold	Proportion of Total Study Population (%)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Positive LR (95% CI)	Negative LR (95% CI)
Total Cohort (Patien	ts with Cough, Fever, Night S	weats, and/or Weigh	t Loss)				
≥1.0	74.5	95.4 (88.6-98.7)	29.9 (25.5-34.6)	22.4 (18.2-27.0)	96.9 (92.1-99.1)	1.4 (1.3-1.5)	0.2 (0.1-0.4)
≥2.0	61.8	87.4 (78.5-93.5)	43.6 (38.7-48.5)	24.7 (20-29.9)	94.2 (89.9-97.1)	1.5 (1.4-1.7)	0.3 (0.2-0.5)
≥3.0	53.6	86.2 (77.1-92.7)	53.3 (48.3-58.2)	28.1 (22.8-33.9)	94.8 (91.1-97.3)	1.8 (1.6-2.1)	0.3 (0.2-0.4)
≥5.0	45.4	75.9 (65.5-84.4)	61.1 (56.2-65.8)	29.2 (23.4-35.6)	92.3 (88.4-95.2)	1.9 (1.6-2.3)	0.4 (0.3-0.6)
≥10.0	35.1	71.3 (60.6-80.5)	72.5 (67.9-76.8)	35.4 (28.4-43.0)	92.3 (88.8-94.9)	2.6 (2.1-3.2)	0.4 (0.3-0.6)
Patients with Cough,	, Fever, and/or Nights Sweats	+/- Weight Loss (Exc	cludes Patients with	s Isolated Weight L	oss)		
≥1 .0	81.9	94.9 (87.4-98.6)	23.6 (17.7-30.5)	34.7 (28.4-41.5)	91.5 (79.6-97.6)	1.2 (1.1-1.4)	0.2 (0.1-0.6)
≥2.0	71.9	87.2 (77.7-93.7)	34.6 (27.7-42)	36.4 (29.5-43.7)	86.3 (76.2-93.2)	1.3 (1.2-1.5)	0.4 (0.2-0.7)
≥3.0	65.4	87.2 (77.7-93.7)	44.0(36.6-51.5)	40.0 (32.6-47.8)	88.9 (80.5-94.5)	1.6 (1.3-1.8)	0.3 (0.2-0.5)
≥5.0	58.8	80.8 (70.3-88.8)	50.5 (43.1-58)	41.2 (33.3-49.4)	86.0 (77.9-91.9)	1.6 (1.4-2.0)	0.4 (0.2-0.6)
≥10.0	49.6	75.6 (64.6-84.7)	61.5 (54.1-68.6)	45.7 (36.9-54.7)	85.5 (78.3-91.0)	2.0 (1.6-2.5)	0.4 (0.3-0.6)
Patients with Isolated	d Weight Loss (Excludes Patie	nts with Cough, Fev	er, or Night Sweats)			
≥1 .0	66.4	100 (66.4-100)	34.9 (28.8-41.5)	5.7 (2.6-10.5)	100.0 (95.5-100.0)	1.5 (1.4-1.7)	0
≥2.0	50.8	88.9 (51.8-99.7)	50.7 (44.0-57.3)	6.6 (2.9-12.6)	99.1 (95.3-100.0)	1.8 (1.4-2.3)	0.2 (0.0-1.4)

Table 4. Utility of C-Reactive Protein Thresholds for Ruling In or Ruling Out Tuberculosis

≥3.0	40.8	77.8 (40.0-97.2)	60.7 (54.0-67.1)	7.2 (3.0-14.3)	98.6 (95.0-99.8)	2 (1.3-2.9)	0.4 (0.1-1.2)
≥5.0	30.7	33.3 (7.5-70.1)	69.4 (63.0-75.3)	4.1 (0.9-11.5)	96.4 (92.3-98.7)	1.1 (0.4-2.8)	1 (0.6-1.5)
≥10.0	19.3	33.3 (7.5-70.1)	81.2 (75.6-86.1)	6.5 (1.4-17.9)	96.9 (93.3-98.8)	1.8 (0.7-4.6)	0.8 (0.5-1.3)

Abbreviations: LR: Likelihood ration; NPV: negative predictive value; PPV positive predictive value





Eligible for SDART w/o TB Eligible for SDART with TB Not eligible for SDART




Figure 2A. Impact of CRP-Based Eligibility Criteria on Same-Day ART Eligibility and Untreated TB in Patients with Cough, Fever,

■ Eligible for SDART w/o TB ■ Eligible for SDART with TB ■ Not eligible for SDART




Figure 2B. Impact of CRP-Based Eligibility Criteria on Same-Day ART Eligibility and Untreated TB in Patients with Isolated Weight

CRP	Proportion of Total	Sensitivity (95%	Specificity (95%	PPV	NPV	Positive LR	Negative LR		
Threshold	Study Population (%)	CI)	CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)		
Patients with	Patients with Cough, Fever, Night Sweats, and/or Weight Loss								
≥1.0	74.5	94.0 (85.4-98.3)	28.5 (24.3-33.1)	17.0 (13.3-21.2)	96.9 (92.1-99.1)	1.3 (1.2-1.4)	0.2 (0.1-0.5)		
≥2.0	61.8	86.6 (76-93.7)	42.0 (37.3-46.8)	18.8 (14.6-23.7)	95.3 (91.2-97.8)	1.5 (1.3-1.7)	0.3 (0.2-0.6)		
≥3.0	53.6	85.1 (74.3-92.6)	51.3 (46.4-56.1)	21.3 (16.6-26.8)	95.7 (92.2-97.9)	1.7 (1.5-2)	0.3 (0.2-0.5)		
≥5.0	45.4	74.6 (62.5-84.5)	59.2 (54.4-63.8)	22.1 (16.9-28.1)	93.8 (90.2-96.3)	1.8 (1.5-2.2)	0.4 (0.3-0.7)		
≥10.0	35.1	70.1 (57.7-80.7)	70.3 (65.7-74.6)	26.9 (20.4-34.1)	93.8 (90.6-96.2)	2.4 (1.9-2.9)	0.4 (0.3-0.6)		
Patients with	Patients with Cough, Fever, and/or Nights Sweats +/- Weight Loss (Excludes Patients with Only Weight Loss)								
≥1.0	81.9	93.2 (83.5-98.1)	21.4 (15.9-27.7)	25.8 (20.1-32.2)	91.5 (79.6-97.6)	1.2 (1.1-1.3)	0.3 (0.1-0.8)		

Supplemental Table 1. Utility of C-Reactive Protein Thresholds for Ruling In or Ruling Out Bacteriologically-Confirmed Tuberculosis*

71.9	86.4 (75.0-94.0)	32.3 (25.9-39.3)	27.3 (21.0-34.3)	89 (79.5-95.1)	1.3 (1.1-1.5)	0.4 (0.2-0.8)
65.4	86.4 (75.0-94.0)	40.8 (33.9-47.9)	30.0 (23.2-37.5)	91.1 (83.2-96.1)	1.5 (1.3-1.7)	0.3 (0.2-0.6)
58.8	79.7 (67.2-89.0)	47.3 (40.2-54.4)	30.7 (23.5-38.7)	88.8(81.2-94.1)	1.5 (1.3-1.8)	0.4 (0.3-0.7)
49.6	74.6 (61.6-85.0)	57.7 (50.6-64.6)	34.1 (26-43)	88.5 (81.8-93.4)	1.8 (1.4-2.2)	0.4 (0.3-0.7)
h Weight Loss Only (Excl	udes Patients with Co	ough, Fever, or Nigi	ht Sweats)	1		
66.4	100 (63.1-100)	34.8 (28.6-41.3)	5.1 (2.2-9.7)	100.0 (95.5-100.0)	1.5 (1.4-1.7)	0.0 (0.0)
50.8	87.5 (47.3-99.7)	50.4 (43.8-57.1)	5.8 (2.4-11.6)	99.1 (95.3-100.0)	1.8 (1.3-2.4)	0.2 (0-1.6)
40.8	75.0 (34.9-96.8)	60.4 (53.8-66.8)	6.2 (2.3-13)	98.6 (95-99.8)	1.9 (1.2-2.9)	0.4 (0.1-1.4)
30.7	37.5 (8.5-75.5)	69.6 (63.2-75.4)	4.1 (0.9-11.5)	97.0 (93.1-99.0)	1.2 (0.5-3.1)	0.9 (0.5-1.5)
19.3	37.5 (8.5-75.5)	81.3 (75.7-86.1)	6.5 (1.4-17.9)	97.4 (94-99.1)	2.0 (0.8-5.1)	0.8 (0.4-1.3)
	65.4 58.8 49.6 <i>Weight Loss Only (Excl</i> 66.4 50.8 40.8 30.7	65.4 86.4 (75.0-94.0) 58.8 79.7 (67.2-89.0) 49.6 74.6 (61.6-85.0) h Weight Loss Only (Excludes Patients with Comparison of the second of the secon	65.4 86.4 (75.0-94.0) 40.8 (33.9-47.9) 58.8 79.7 (67.2-89.0) 47.3 (40.2-54.4) 49.6 74.6 (61.6-85.0) 57.7 (50.6-64.6) h Weight Loss Only (Excludes Patients with Cough, Fever, or Night Loss Only (Excludes Patients with Cough, Fever, or Night Cough, Fever, or Night Cough (Excludes Patients with Cough, Fever, or Night Cough (Excludes Patients Vith (65.4 86.4 (75.0-94.0) 40.8 (33.9-47.9) 30.0 (23.2-37.5) 58.8 79.7 (67.2-89.0) 47.3 (40.2-54.4) 30.7 (23.5-38.7) 49.6 74.6 (61.6-85.0) 57.7 (50.6-64.6) 34.1 (26-43) <i>Weight Loss Only (Excludes Patients with Cough, Fever, or Night Sweats)</i> 66.4 100 (63.1-100) 34.8 (28.6-41.3) 5.1 (2.2-9.7) 50.8 87.5 (47.3-99.7) 50.4 (43.8-57.1) 5.8 (2.4-11.6) 40.8 75.0 (34.9-96.8) 60.4 (53.8-66.8) 6.2 (2.3-13) 30.7 37.5 (8.5-75.5) 69.6 (63.2-75.4) 4.1 (0.9-11.5)	65.4 86.4 (75.0-94.0) 40.8 (33.9-47.9) 30.0 (23.2-37.5) 91.1 (83.2-96.1) 58.8 79.7 (67.2-89.0) 47.3 (40.2-54.4) 30.7 (23.5-38.7) 88.8(81.2-94.1) 49.6 74.6 (61.6-85.0) 57.7 (50.6-64.6) 34.1 (26-43) 88.5 (81.8-93.4) b Weight Loss Only (Excludes Patients with Cough, Fever, or Night Sweats) 66.4 100 (63.1-100) 34.8 (28.6-41.3) 5.1 (2.2-9.7) 100.0 (95.5-100.0) 50.8 87.5 (47.3-99.7) 50.4 (43.8-57.1) 5.8 (2.4-11.6) 99.1 (95.3-100.0) 40.8 75.0 (34.9-96.8) 60.4 (53.8-66.8) 6.2 (2.3-13) 98.6 (95-99.8) 30.7 37.5 (8.5-75.5) 69.6 (63.2-75.4) 4.1 (0.9-11.5) 97.0 (93.1-99.0)	65.4 86.4 (75.0-94.0) 40.8 (33.9-47.9) 30.0 (23.2-37.5) 91.1 (83.2-96.1) 1.5 (1.3-1.7) 58.8 79.7 (67.2-89.0) 47.3 (40.2-54.4) 30.7 (23.5-38.7) 88.8(81.2-94.1) 1.5 (1.3-1.8) 49.6 74.6 (61.6-85.0) 57.7 (50.6-64.6) 34.1 (26-43) 88.5 (81.8-93.4) 1.8 (1.4-2.2) <i>Weight Loss Only (Excludes Patients with Cough, Fever, or Night Sweats)</i> 51. (2.2-9.7) 100.0 (95.5-100.0) 1.5 (1.4-1.7) 50.8 87.5 (47.3-99.7) 50.4 (43.8-57.1) 5.8 (2.4-11.6) 99.1 (95.3-100.0) 1.8 (1.3-2.4) 40.8 75.0 (34.9-96.8) 60.4 (53.8-66.8) 6.2 (2.3-13) 98.6 (95-99.8) 1.9 (1.2-2.9) 30.7 37.5 (8.5-75.5) 69.6 (63.2-75.4) 4.1 (0.9-11.5) 97.0 (93.1-99.0) 1.2 (0.5-3.1)

*Bacteriologically-confirmed tuberculosis required a positive Xpert Ultra test and/or mycobacterial culture